The stock of Second Sight Medical Products Inc (NASDAQ:EYES) hit a new 52-week low and has $2.09 target or 14.00% below today’s $2.43 share price. The 7 months bearish chart indicates high risk for the $97.32M company. The 1-year low was reported on Nov, 1 by Barchart.com. If the $2.09 price target is reached, the company will be worth $13.62M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 286,531 shares traded hands. Second Sight Medical Products Inc (NASDAQ:EYES) has declined 47.59% since March 30, 2016 and is downtrending. It has underperformed by 50.60% the S&P500.
Analysts await Second Sight Medical Products Inc (NASDAQ:EYES) to report earnings on November, 3. They expect $-0.16 EPS, down 23.08% or $0.03 from last year’s $-0.13 per share. After $-0.19 actual EPS reported by Second Sight Medical Products Inc for the previous quarter, Wall Street now forecasts -15.79% EPS growth.
According to Zacks Investment Research, “Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California.”
Another recent and important Second Sight Medical Products Inc (NASDAQ:EYES) news was published by Businesswire.com which published an article titled: “Second Sight Medical Products, Inc. Announces Completion of Oversubscribed …” on June 01, 2016.
EYES Company Profile
Second Sight Medical Products, Inc., incorporated on May 22, 2003, is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.